| Patient | Mildred Ella Didrikson Zaharias |
|---|---|
| Date of birth | 1911-06-26 |
| Identifiers | MRN HR-ML038-SYN-TD; SSN (made up) 000-38-4471 |
| Document date | 1953-10-05 |
| Author | Rosalind Vasquez-Thornbury, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Final restaging after nine doses of dostarlimab. [S]
Ms. Didrikson Zaharias returns two weeks after her ninth and last dose of dostarlimab. Final restaging last week showed only fibrosis on MRI, no metastases on CT, and a flat white scar with no ulcer on sigmoidoscopy. She has had no bleeding, urgency or change in bowel habit for five months, and no diarrhea, rash, cough or breathlessness. She takes levothyroxine 75 micrograms each morning, has no tiredness or cold intolerance, and is still taking ferrous sulfate. The second hepatitis B vaccine dose was given with the last dose of dostarlimab. She played four tournaments over the summer and won a regional event last month. She asked what watch-and-wait means and how she will know if the cancer comes back. [S]
| Element | Detail |
|---|---|
| Treatment | Nine doses of dostarlimab over six months, completed two weeks ago |
| Restaging | MRI: complete response; CT: no metastases; sigmoidoscopy: flat white scar, no ulcer |
| Adverse events | Immune-related hypothyroidism, replaced; nothing else |
| Sport | Competing; won a regional event last month |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight 63.4 kg, steady |
| Gastrointestinal | Negative | Normal bowel movements; no bleeding, urgency or leakage |
| Endocrine | Negative | No cold intolerance or palpitations |
| Genitourinary | Negative | Sex comfortable; no urinary symptoms |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Negative | Relieved; some worry before each scan; PHQ-9 2, GAD-7 3; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning | One tablet every other morning | Oral route | 1953-03-30 | active | S |
| Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months) | 500 mg every 3 weeks for nine doses | Intravenous route | 1953-04-06 to 1953-09-21 | completed | S |
| Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from iron | One tablet each morning | Oral route | 1953-06-29 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1953-10-05 | Body height | 168 | cm | S |
| 1953-10-05 | Body weight | 63.4 | kg | S |
| 1953-10-05 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 1953-10-05 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1953-10-05 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1953-10-05 | Heart rate | 64 | /min | S |
| 1953-10-05 | Respiratory rate | 14 | /min | S |
| 1953-10-05 | Body temperature | 36.6 | Cel | S |
| 1953-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1953-10-05 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 12-15.5 g/dL | Normal | S |
| 1953-10-05 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 86 | fL | 80-100 fL | Normal | S |
| 1953-10-05 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1953-10-05 | Platelets [#/volume] in Blood by Automated count | 255 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1953-10-05 | Creatinine [Mass/volume] in Serum or Plasma | 0.77 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1953-10-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M | 99 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1953-10-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 7-35 U/L | Normal | S |
| 1953-10-05 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 8-35 U/L | Normal | S |
| 1953-10-05 | Ferritin [Mass/volume] in Serum or Plasma | 41 | ng/mL | 15-150 ng/mL | Normal | S |
| 1953-10-05 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1953-10-05 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1953-10-05 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 1.6 | ng/mL | Up to 3.0 ng/mL in non-smokers | Normal | S |
| 1953-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 1953-10-05 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S |
Vital signs recorded on 1953-10-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Fit and well; weight 63.4 kg; blood pressure 112/70, pulse 64 |
| Neck | Thyroid not enlarged |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Abdomen | Soft, non-tender; no liver enlargement or mass |
| Rectal | With her agreement and a chaperone: smooth, supple wall; no mass, nodule or ulcer; normal sphincter tone; no blood |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this week | resolved | confirmed | K62.5 | S — Synthetic presenting problem anchored to the documented fatigue before her cancer diagnosis. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tiredness | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented fatigue at the end of the 1952 season. |
| Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactly | active | confirmed | C20 | S — Synthetic histology, site, stage, mismatch repair status and course; the sources say she had cancer treated with a colostomy and call it colon cancer (R on the site). See sources.md. |
| Acute viral upper respiratory infection with cough and sore throat, a week before cycle 4 of dostarlimab; oxygen saturation and chest X-ray normal, so immune-related pneumonitis is unlikely; rapid influenza and COVID-19 tests negative; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness; not a historical claim. |
| Immune-related primary hypothyroidism from dostarlimab, grade 2: tiredness and cold hands, TSH 12.6 mIU/L and free T4 0.6 ng/dL after four doses, following a mild TSH rise four weeks earlier; dostarlimab continued | active | confirmed | E03.2 | S — Synthetic common immune-related adverse event of PD-1 blockade. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Final restaging pelvic MRI, CT of the chest, abdomen and pelvis, and flexible sigmoidoscopy | After the last dose | Up to date | Last week: complete response on MRI and endoscopy; no metastases on CT |
| Examination | Digital rectal examination | At each oncology visit during treatment; every three to four months in watch-and-wait | Completed today | Normal; no mass or ulcer |
| Laboratory | CEA | At diagnosis, at each restaging, then every three to six months for two years | Completed today | 1.6 ng/mL |
| Laboratory | Blood count | After treatment and with surveillance | Completed today | Hemoglobin 13.4 g/dL, MCV 86 fL, white cells 6.1, platelets 255 |
| Laboratory | Ferritin after oral iron | About three months after starting | Completed today | 41 ng/mL, drawn late (deviation recorded at the fourth visit) |
| Laboratory | Kidney and liver function | After PD-1 blockade | Completed today | Creatinine 0.77 mg/dL, eGFR 99; ALT 19, AST 21 U/L |
| Laboratory | TSH and free T4 | At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine change | Completed today | TSH 2.4 mIU/L, free T4 1.2 ng/dL on levothyroxine 75 micrograms |
| Laboratory | TSH and free T4 with the ninth dose | Every six weeks on PD-1 blockade | Deferred | Missed: the thyroid tests due with the ninth dose, six weeks after the preventive visit, were not on the infusion order. No harm resulted, since the TSH today, eight weeks after the last check, is in range on an unchanged dose; corrective action: thyroid tests added to her standing surveillance order set, and the infusion center's PD-1 order set reviewed so that thyroid tests repeat automatically every six weeks |
| Imaging | Pelvic MRI in watch-and-wait | Every six months for two to three years | Due | Next in six months |
| Imaging | Flexible sigmoidoscopy in watch-and-wait | Every three to four months for two years, then every six months to five years | Due | Next in three months |
| Imaging | CT of the chest, abdomen and pelvis | Every six to twelve months for five years | Due | Next in six to twelve months |
| Imaging | Colonoscopy | At one year | Due | Next in one year |
| Self-management | Survivorship care plan | Within a year of completing treatment | Completed today | Written treatment summary, surveillance schedule and warning signs given to her |
| Self-management | Bowel function (low anterior resection syndrome, incontinence) | After rectal surgery or radiation | Not indicated | No surgery or radiation; bowel function normal |
| Referral | Wound-ostomy nursing | If a stoma is created | Not indicated | No stoma |
| Self-management | Sexual function and fertility | Through survivorship | Completed today | Sex comfortable; contraception continued for four months after the last dose; not planning a pregnancy |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and at least yearly | Completed today | PHQ-9 2 (item 9 scored 0), GAD-7 3 |
| Self-management | Lifestyle: activity, diet and alcohol | Each visit | Completed today | Golf and strength work most days; red meat cut back; alcohol rare |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Rex DK, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112(7):1016-1030 (PMID 28555630) (2017); CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026)
Follow-up: Sigmoidoscopy and examination in three months; MRI in six months; primary care review in three months with TSH at six months. [S]